Develops monoclonal and bispecific antibodies that block an immune-cell receptor for people with inflammatory and immune-mediated diseases.
10-K for FY2025, filed Mar 5, 2026
Licensees pay for rights to research, develop and commercialize product candidates; upfront fees are tied to transfer of the license, milestone payments to specified events, and royalties to related sales. Payments for research services come as the related work is done.
10-K for FY2025, filed Mar 5, 2026License Revenue: License revenue is generated from granting third parties rights to certain of the Company’s intellectual property…View ↗
Up-front License Fees: If a license is determined to be distinct from the other performance obligations identified in the arrangement, the…View ↗
Milestone Payments: At the inception of an agreement that includes research and development milestone payments, the Company evaluates each…View ↗
Royalties: For arrangements that include sales-based royalties, including milestone payments based on a level of sales, and the license is…View ↗
Research and Development Services: The Company will record costs associated with development and process optimization activities as…View ↗
$1M
10-K for FY2025, filed Mar 5, 2026
$1M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Related party license revenue
Licensed
10-K for FY2025, filed Mar 5, 2026 |
100% |
Related party license revenue, FY2025
$1M Sources
|
Licensed |
|
Collaboration revenue:
|
0.0% |
Collaboration revenue:, FY2025
$0 Sources
|
Licensees obtain rights to Shattuck’s intellectual property; collaboration arrangements can also cover research, development and manufacturing services.
10-K for FY2025, filed Mar 5, 2026Collaboration revenue is recognized in accordance with ASC 606, Revenue from Contracts with Customers (“ASC 606”). Arrangements with…View ↗
At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services…View ↗
License Revenue: License revenue is generated from granting third parties rights to certain of the Company’s intellectual property…View ↗
No. It lost $48.8M in FY2025.
Shrinking. Revenue fell 97% in 4 years, from $30M in FY2021 to $1M in FY2025, about 57% a year.
From fusion proteins to receptor-blocking antibodies
The older report focused on dual-sided fusion proteins for cancer and immune therapies, including its ARC and GADLEN platforms. The latest report centers on monoclonal and bispecific antibodies that block a receptor for inflammatory and immune-mediated diseases.
10-K for FY2022, filed Feb 23, 2023 10-K for FY2025, filed Mar 5, 2026
Competes with Abbvie, Johnson & Johnson, Merck, Novartis, Pfizer, Roche/Genentech, Sanofi, Teva, Takeda, Hoffmann-La Roche, Spyre Therapeutics, Xencor, and Absci
10-K for FY2025, filed Mar 5, 2026We compete in the segments of the pharmaceutical, biotechnology, and other related markets that develop therapies for immune-mediated…View ↗
Loading...